Pharmaceuticals News and Research

RSS

Former Member of Congress joins Lung Cancer Alliance

Today, Lung Cancer Alliance (LCA) proudly announced that The Honorable Michael G. Oxley has agreed to join its Board of Directors. Oxley, a former Member of Congress, joins LCA, the only national organization dedicated solely to all those either living with or at risk for lung cancer, as it prepares to begin its sixth year of patient support and advocacy headquartered in Washington, DC.

30 Oct 2010

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.

30 Oct 2010

Presidio to present PPI-461 data for HCV infection at AASLD meeting

Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.

30 Oct 2010

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

Pharmaceutical Strategic Initiatives announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.

30 Oct 2010

CONCERTA improves handwriting performance in children with ADHD: Study

Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.

30 Oct 2010

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

Cipher Pharmaceuticals Inc. today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne.

30 Oct 2010

AACR announces launch of new journal, Cancer Discovery

The American Association for Cancer Research announces the launch of its newest journal, Cancer Discovery, which will publish high-impact, peer-reviewed articles describing major advances in basic and clinical research. Its unique format will feature game-changing research, review articles, perspectives and commentaries, news, and "Research Watch" summaries of important journal articles. Cancer Discovery is a new addition to the AACR's robust publication program.

30 Oct 2010

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.

30 Oct 2010

Hikma to acquire Baxter's US generic injectables business

Hikma Pharmaceuticals PLC ("Hikma"), the fast growing multinational pharmaceutical group, announces that it has signed an agreement to acquire Baxter Healthcare Corporation's US generic injectables business ("Multi-Source Injectables" or the "Business") for a cash consideration of $112 million.

30 Oct 2010

Adesso enters multi-year contract with Novartis

Adesso Solutions, the leader in integrated technology solutions for the Consumer Goods industry, today announced that a new multi-year contract has been signed with global pharmaceutical leader, Novartis AG.

30 Oct 2010

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

Idera Pharmaceuticals, Inc. today announced a presentation describing the chemistry and immunological activity of its proprietary Toll-Like Receptor (TLR) 3 agonist compounds and the use of these compounds as vaccine adjuvants in a preclinical model.

30 Oct 2010

NeoPharm enters merger agreement with Insys Therapeutics

NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.

30 Oct 2010

Agilent opens new life sciences instruments manufacturing facility in Singapore

Agilent Technologies Inc. today announced the opening of its new life sciences instruments manufacturing facility in Singapore. The facility will produce the company's Liquid Chromatography/Mass Spectrometry (LC/MS) instruments for the global market.

30 Oct 2010

Inter Press Service reports on counterfeit medicine challenges in central, Eastern Europe

Central and Eastern Europe is facing 'significant challenges' in combating a multi-billion euro, and often lethal, trade in fake medicines, security and pharmaceutical groups have warned, Inter Press Service reports in an article that examines the scope of the problem in a region now identified as a key smuggling route in an illicit trade which is growing every year.

30 Oct 2010

AVEO to raise $61 million through private placement

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the execution of a securities purchase agreement with a select group of institutional and accredited investors providing for a private placement, or PIPE financing.

30 Oct 2010

APP receives FDA marketing approval for Metoprolol Tartrate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Metoprolol Tartrate Injection, USP, and expects to launch the medication soon.

30 Oct 2010

FDA approves NUEDEXTA capsules for pseudobulbar affect

AVANIR Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.

30 Oct 2010

Idenix third quarter total revenue increases from $3.1 million to $3.8 million

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2010.

30 Oct 2010

Taro third quarter net sales increases 10.0% to $103.2 million

Taro Pharmaceutical Industries Ltd. today provided preliminary, unaudited and unreviewed financial results for the third quarter and nine months ended September 30, 2010.

30 Oct 2010

Caraco third quarter net sales increases from $78.4 million to $97.8 million

Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $97.8 million and $227.8 million during the second quarter ended September 30, 2010 and first six months of the Company's current fiscal year ended September 30, 2010, respectively, as compared to $78.4 million and $126.4 million, respectively, for the corresponding periods of the previous fiscal year ended September 30, 2009.

30 Oct 2010